NeoGenomics Appoints Carolyn Starrett to Board of Directors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 25 2026
0mins
NeoGenomics announced the appointment of Carolyn Starrett to its Board of Directors. Starrett is currently the President of Starrett Advisory, an independent consulting and strategic advisory firm
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NEO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NEO
Wall Street analysts forecast NEO stock price to fall
11 Analyst Rating
5 Buy
6 Hold
0 Sell
Moderate Buy
Current: 15.160
Low
12.00
Averages
14.00
High
16.00
Current: 15.160
Low
12.00
Averages
14.00
High
16.00
About NEO
NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing, interpretation and consultative services, molecular and NGS testing, comprehensive technical and professional services offering, clinical trials and research, validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics, Fluorescence In-Situ Hybridization (FISH), Flow cytometry, Molecular testing and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NeoGenomics Appoints Carolyn Starrett to Board of Directors
- New Board Member: NeoGenomics has appointed Carolyn Starrett to its Board of Directors, bringing over 25 years of experience in commercial, product, and operations roles at data and technology companies, particularly in AI and data insights in cancer care, which is expected to provide strategic guidance to the company.
- Rich Leadership Experience: Having served as CEO and Board Director at Flatiron Health, Starrett was instrumental in driving innovation in cancer care, and her addition is anticipated to accelerate NeoGenomics' expansion in precision medicine, enhancing the company's competitive position in the market.
- Strategic Advisory Role: As President of Starrett Advisory, she will leverage her expertise at the intersection of healthcare delivery, drug development, and data analytics to help NeoGenomics formulate effective strategies in a rapidly evolving healthcare landscape, thereby increasing the company's market adaptability.
- Industry Influence: Starrett's experience on the board of Foundation Medicine and her leadership roles at Boston Consulting Group demonstrate her capability in driving innovation in medical technology, which is expected to positively impact NeoGenomics' product portfolio and market influence.
See More
NeoGenomics Prices $275M Convertible Notes Offering Due 2032
- Offering Size: NeoGenomics has successfully priced a $275 million offering of 0.75% convertible senior notes, expected to close on June 22, 2026, providing the company with substantial funding for future growth initiatives.
- Interest and Maturity: The notes carry an annual interest rate of 0.75%, payable semiannually starting January 1, 2027, with a maturity date of July 1, 2032, unless converted or redeemed earlier, ensuring a low-cost financing option for the company.
- Conversion Terms: The initial conversion rate is set at 70.6140 shares of common stock per $1,000 principal amount, translating to an initial conversion price of approximately $14.16 per share, representing a 35% premium over the last reported sale price of $10.49 on June 16, 2026, indicating strong market confidence in the company's future.
- Use of Proceeds: The net proceeds of approximately $266.15 million will be allocated to cover $25 million in capped call transaction costs and to repurchase $276 million of 0.25% convertible senior notes due 2028, aimed at reducing potential dilution and optimizing the capital structure.
See More
NeoGenomics Announces $275 Million Convertible Notes Offering
- Convertible Notes Offering: NeoGenomics announced a $275 million offering of 0.75% convertible senior notes, expected to close on June 22, 2026, which will enhance the company's capital structure and support future growth initiatives.
- Conversion Terms Advantage: The initial conversion price of approximately $14.16 per share represents a 35% premium over the current stock price, providing investors with potential capital appreciation opportunities while possibly boosting the company's stock price.
- Planned Use of Proceeds: The estimated net proceeds of approximately $266.15 million will be allocated with $25 million for capped call transaction costs, while the remainder will be used for repurchasing existing convertible notes and shares, aiming to optimize capital allocation.
- Market Impact Expectations: The concurrent repurchase of existing debt and stock may lead to an increase in the company's stock price, thereby raising the initial conversion price of the notes, enhancing investor confidence and improving market performance.
See More
NeoGenomics Announces $275M Convertible Notes Offering
- Offering Size: NeoGenomics has announced a private offering of $275 million in convertible senior notes, with initial purchasers having the option to buy an additional $41.25 million within 13 days of issuance, which will enhance the company's capital structure and provide funding for future investments.
- Debt Maturity: The notes will mature on July 1, 2032, as senior unsecured obligations, which is expected to provide the company with flexible financing options to optimize its financial position over the coming years.
- Repurchase Plans: The company plans to use part of the proceeds to repurchase existing 0.25% convertible notes, which is expected to reduce future interest expenses, while also potentially using cash and proceeds to repurchase up to $25 million of its common stock, thereby enhancing shareholder value.
- Diverse Use of Funds: Remaining proceeds will be allocated for general corporate purposes, indicating the company's flexible strategy in capital allocation to support its long-term growth objectives and operational needs.
See More
Stifel Canada Raises Neo Price Target to $44
- Price Target Upgrade: Stifel Canada has raised its price target for Neo Performance Materials to $44, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Positive Market Reaction: This price target increase could have a favorable impact on Neo's stock price, boosting investor confidence and potentially enhancing its performance in the capital markets.
- Industry Outlook: With the rising demand for rare earth materials, Neo Performance Materials may further solidify its position in the industry, promoting long-term company growth.
- Analyst Confidence: Stifel Canada's action indicates a bullish sentiment among analysts regarding Neo's future performance, which may lead other institutions to adjust their investment strategies accordingly.
See More
Neo Performance Materials Analysts Significantly Upgrade Revenue Estimates
- Revenue Upgrade: Analysts have raised Neo Performance Materials' 2026 revenue forecast from $526 million to $587 million, reflecting a significant 15% increase that indicates a substantial enhancement in the company's sales capabilities, potentially driving the stock price higher.
- Earnings Improvement: The expected earnings per share for 2026 is now projected at $0.50, up from the previous estimate of $0.48, demonstrating an increase in the company's profitability and boosting investor confidence.
- Price Target Increase: Analysts have lifted the price target by 32% to $27.15, with the most optimistic analyst setting a target of $30.25 and the most pessimistic at $22.64, indicating a strong consensus on the company's value due to the tight range of estimates.
- Industry Growth Comparison: Neo Performance Materials is forecasted to achieve a 20% annual growth rate moving forward, significantly better than the 1.4% decline over the past five years and exceeding the broader industry’s expected 1.8% annual growth, highlighting the company's competitive advantage in the market.
See More
NeoGenomics Appoints Carolyn Starrett to Board of Directors
- New Board Member: NeoGenomics has appointed Carolyn Starrett to its Board of Directors, bringing over 25 years of experience in commercial, product, and operations roles at data and technology companies, particularly in AI and data insights in cancer care, which is expected to provide strategic guidance to the company.
- Rich Leadership Experience: Having served as CEO and Board Director at Flatiron Health, Starrett was instrumental in driving innovation in cancer care, and her addition is anticipated to accelerate NeoGenomics' expansion in precision medicine, enhancing the company's competitive position in the market.
- Strategic Advisory Role: As President of Starrett Advisory, she will leverage her expertise at the intersection of healthcare delivery, drug development, and data analytics to help NeoGenomics formulate effective strategies in a rapidly evolving healthcare landscape, thereby increasing the company's market adaptability.
- Industry Influence: Starrett's experience on the board of Foundation Medicine and her leadership roles at Boston Consulting Group demonstrate her capability in driving innovation in medical technology, which is expected to positively impact NeoGenomics' product portfolio and market influence.
See More
NeoGenomics Prices $275M Convertible Notes Offering Due 2032
- Offering Size: NeoGenomics has successfully priced a $275 million offering of 0.75% convertible senior notes, expected to close on June 22, 2026, providing the company with substantial funding for future growth initiatives.
- Interest and Maturity: The notes carry an annual interest rate of 0.75%, payable semiannually starting January 1, 2027, with a maturity date of July 1, 2032, unless converted or redeemed earlier, ensuring a low-cost financing option for the company.
- Conversion Terms: The initial conversion rate is set at 70.6140 shares of common stock per $1,000 principal amount, translating to an initial conversion price of approximately $14.16 per share, representing a 35% premium over the last reported sale price of $10.49 on June 16, 2026, indicating strong market confidence in the company's future.
- Use of Proceeds: The net proceeds of approximately $266.15 million will be allocated to cover $25 million in capped call transaction costs and to repurchase $276 million of 0.25% convertible senior notes due 2028, aimed at reducing potential dilution and optimizing the capital structure.
See More
NeoGenomics Announces $275 Million Convertible Notes Offering
- Convertible Notes Offering: NeoGenomics announced a $275 million offering of 0.75% convertible senior notes, expected to close on June 22, 2026, which will enhance the company's capital structure and support future growth initiatives.
- Conversion Terms Advantage: The initial conversion price of approximately $14.16 per share represents a 35% premium over the current stock price, providing investors with potential capital appreciation opportunities while possibly boosting the company's stock price.
- Planned Use of Proceeds: The estimated net proceeds of approximately $266.15 million will be allocated with $25 million for capped call transaction costs, while the remainder will be used for repurchasing existing convertible notes and shares, aiming to optimize capital allocation.
- Market Impact Expectations: The concurrent repurchase of existing debt and stock may lead to an increase in the company's stock price, thereby raising the initial conversion price of the notes, enhancing investor confidence and improving market performance.
See More
NeoGenomics Announces $275M Convertible Notes Offering
- Offering Size: NeoGenomics has announced a private offering of $275 million in convertible senior notes, with initial purchasers having the option to buy an additional $41.25 million within 13 days of issuance, which will enhance the company's capital structure and provide funding for future investments.
- Debt Maturity: The notes will mature on July 1, 2032, as senior unsecured obligations, which is expected to provide the company with flexible financing options to optimize its financial position over the coming years.
- Repurchase Plans: The company plans to use part of the proceeds to repurchase existing 0.25% convertible notes, which is expected to reduce future interest expenses, while also potentially using cash and proceeds to repurchase up to $25 million of its common stock, thereby enhancing shareholder value.
- Diverse Use of Funds: Remaining proceeds will be allocated for general corporate purposes, indicating the company's flexible strategy in capital allocation to support its long-term growth objectives and operational needs.
See More
Stifel Canada Raises Neo Price Target to $44
- Price Target Upgrade: Stifel Canada has raised its price target for Neo Performance Materials to $44, reflecting a positive outlook on the company's future growth potential, which may attract more investor interest.
- Positive Market Reaction: This price target increase could have a favorable impact on Neo's stock price, boosting investor confidence and potentially enhancing its performance in the capital markets.
- Industry Outlook: With the rising demand for rare earth materials, Neo Performance Materials may further solidify its position in the industry, promoting long-term company growth.
- Analyst Confidence: Stifel Canada's action indicates a bullish sentiment among analysts regarding Neo's future performance, which may lead other institutions to adjust their investment strategies accordingly.
See More
Neo Performance Materials Analysts Significantly Upgrade Revenue Estimates
- Revenue Upgrade: Analysts have raised Neo Performance Materials' 2026 revenue forecast from $526 million to $587 million, reflecting a significant 15% increase that indicates a substantial enhancement in the company's sales capabilities, potentially driving the stock price higher.
- Earnings Improvement: The expected earnings per share for 2026 is now projected at $0.50, up from the previous estimate of $0.48, demonstrating an increase in the company's profitability and boosting investor confidence.
- Price Target Increase: Analysts have lifted the price target by 32% to $27.15, with the most optimistic analyst setting a target of $30.25 and the most pessimistic at $22.64, indicating a strong consensus on the company's value due to the tight range of estimates.
- Industry Growth Comparison: Neo Performance Materials is forecasted to achieve a 20% annual growth rate moving forward, significantly better than the 1.4% decline over the past five years and exceeding the broader industry’s expected 1.8% annual growth, highlighting the company's competitive advantage in the market.
See More
